What Type of β-Blocker Should Be Used to Treat Chronic Heart Failure?
- 1 August 2000
- journal article
- editorial
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (5) , 484-486
- https://doi.org/10.1161/01.cir.102.5.484
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Myocardial-Directed Overexpression of the Human β1-Adrenergic Receptor in Transgenic MiceJournal of Molecular and Cellular Cardiology, 2000
- Early and Delayed Consequences of β 2 -Adrenergic Receptor Overexpression in Mouse HeartsCirculation, 2000
- Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted miceProceedings of the National Academy of Sciences, 1998
- Improvement of Postreceptor Events by Metoprolol Treatment in Patients With Chronic Heart FailureJournal of the American College of Cardiology, 1997
- Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized studyJournal of the American College of Cardiology, 1995
- Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathyJournal of the American College of Cardiology, 1994
- Beneficial effects of metoprolol in idiopathic dilated cardiomyopathyThe Lancet, 1993
- Changes in myocardial and vascular receptors in heart failureJournal of the American College of Cardiology, 1993
- Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agentsThe American Journal of Cardiology, 1993
- $beta;-Adrenergic function in heart muscle disease and heart failureJournal of Molecular and Cellular Cardiology, 1985